Chris Gibson, Recursion CEO (Vaughn Ridley/Sportsfile for Web Summit via Getty Images)

Re­cur­sion ac­quires two AI-based drug dis­cov­ery com­pa­nies in $87.5M deal

AI drug de­vel­op­er Re­cur­sion Phar­ma­ceu­ti­cals has brought two more AI-fo­cused com­pa­nies with their own dis­cov­ery plat­forms un­der its wing in an ac­qui­si­tion worth $87.5 mil­lion, the com­pa­ny an­nounced to­day.

Re­cur­sion is buy­ing both com­pa­nies, Cycli­ca and Va­lence, most­ly in eq­ui­ty. The deals come as in­sid­ers pre­dict a surge in biotech M&A — with small­er play­ers, not just Big Phar­ma, ready to jump on tuck-in ac­qui­si­tions of even small­er com­pa­nies.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.